Ildong Pharmaceutical Co., Ltd.
249420.KS · Korea Exchange · KRW
12.760,00KRW
+510,00 (+4,16 %)Stand 10. Nov., 6:30
Kennzahlen
- Eröffnung
- 12.390,00
- Vortag
- 12.250,00
- Tagesspanne
- 12.390,00 – 12.840,00
- 52 Wochen
- 11.250,00 – 45.050,00
- Volumen
- 91.267
- Ø Volumen
- 247.523
- Börsenwert
- 402,04 Mrd. KRW
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,8
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio includes various medications such as anti-diarrheal agents, antibiotics, antifungals, antivirals, antihistamines, anticancer drugs, NSAIDs, and pain relievers, along with essential vitamins, minerals, and nutritional supplements. The company also produces treatments for numerous bodily systems, including cardiovascular, central nervous, dental, endocrine, gastrointestinal, respiratory, topical, and urogenital health, as well as those for blood circulation. Beyond pharmaceuticals, Ildong offers raw material drugs, health foods, cosmetics, and specialized medical devices, such as scar treatment products. Their range also extends to unique treatments for conditions like osteoarthritis, wound care, artificial tears, and feminine hygiene products. In addition to its product offerings, the company manages licenses and provides contract manufacturing services. With a global reach, Ildong Pharmaceutical exports its products to approximately 20 countries. Furthermore, the company has entered into a strategic collaboration with Evotec SE, leveraging Evotec's INDiGO platform to accelerate the development of its proprietary projects.
- CEO
- Yun Paul Woongsup
- Mitarbeitende
- 1.104
- Hauptsitz
- Seoul, SL, KR
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 31. Aug. 2016
- Website
- ildong.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.